ロード中...
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe
OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-...
保存先:
| 出版年: | Rheumatology (Oxford) |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7785316/ https://ncbi.nlm.nih.gov/pubmed/32584415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/keaa181 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|